Santhera Pharmaceuticals Holding AG (XSWX:SANN)

Full Year 2025 Santhera Pharmaceuticals Holding AG Earnings Call Transcript

Apr 28, 2026 / 12:00 PM GMT

Release Date Price: CHF18.54 (+0.98%)

Transcript

Key Points

Positve

Santhera Pharmaceuticals Holding AG (SPHDF) reported a significant revenue increase, nearly doubling to 77.2 million, surpassing their initial guidance.
The company achieved strong market penetration in Germany and Austria, with over 40% and 50% market share respectively in the glucocorticoid steroid market.
Santhera has secured reimbursement agreements in key European markets, including Spain and Italy, with launches expected soon.
The Guardian study results presented at the MDA conference showed promising long-term efficacy and safety data, enhancing the drug's differentiation and market potential.
Santhera expanded its global footprint by signing distribution partnerships in GCC, India, Turkey, and Russia, and is in late-stage negotiations for Latin America.

Negative

The company faces a 17% price reduction in Germany, which was pre-agreed, impacting revenue from that market.
There are delays in securing reimbursement in the Nordics and France, with France expected to be the last European country to have reimbursement.
Santhera's operating loss increased to 37.6 million, attributed to higher cost of goods and milestone payments.
The company anticipates a reduction in revenue from supply and services due to Catalyst establishing its own manufacturing capabilities.
There is uncertainty regarding the timing and necessity of additional studies for product launch in Japan, which could delay market entry.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SANN.S - Santhera Pharmaceuticals Holding AG
Full Year 2025 Santhera Pharmaceuticals Holding AG Earnings Call
Apr 28, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Santhera Pharmaceuticals investor presentation. Throughout this recorded presentation, investors will be in listen-only mode. Questions are encouraged and could be submitted at any time via the Q&A tab situated on the right-hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so.

Before we begin, I'd like to submit the following poll.

I'd now like to hand you over to the management team. Dario, good morning, sir.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.